Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and efficacy of GSK Neisseria gonorrhoeae GMMA (NgG) investigational vaccine in healthy adults
2022-500883-37-00Phase 2Completed
- Sponsor
- GSK
- Start
- May 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 8
01
Overview
Phase 2 trial of NgG vaccine in gonorrhea, sponsored by GSK. Started May 2023; status: completed.
02
Drugs
NgG vaccine
03
Conditions
gonorrhea
Beyond the preview
Go deeper on 2022-500883-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500883-37-00.